SCHEMBL26784147

SCHEMBL26784147

CCc1c(C)sc(C)c1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
KDM4E B2RXH2 4/20 0.44
CYP1A2 P05177 1/20 0.44
MAPT P10636 6/20 0.39
HPGD P15428 5/20 0.39
MAPK1 P28482 2/20 0.39
HSD17B10 Q99714 5/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALOX15 P16050 1/20 0.38
CNR2 P34972 3/20 0.37
TSHR P16473 2/20 0.37
RECQL P46063 1/20 0.37
XIAP P98170 1/20 0.37
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
FHIT P49789 1/20 0.36
TDP1 Q9NUW8 3/20 0.36
POLB P06746 2/20 0.36
ABCC1 P33527 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8201854 0.82 FHIT (0.49) ALDH1A1KDM4ECYP1A2MAPTHPGD
SCHEMBL5080674 0.78 DAO (0.42) ALDH1A1KDM4ECYP1A2MAPTHPGD
SCHEMBL29180339 0.77 ALDH1A1 (0.38) ALDH1A1KDM4ECYP1A2HSD17B10RECQL
SCHEMBL27932259 0.75 ALDH1A1 (0.37) ALDH1A1KDM4ECYP1A2HSD17B10SMN1; SMN2
SCHEMBL8573447 0.73 ALDH1A1 (0.39) ALDH1A1CYP1A2HSD17B10NOTUMNPSR1
SCHEMBL1009054 0.73 ALDH1A1 (0.39) ALDH1A1CYP1A2HSD17B10NOTUMNPSR1
SCHEMBL13343473 0.73 ALDH1A1 (0.36) ALDH1A1KDM4ECYP1A2HSD17B10RECQL
SCHEMBL13711828 0.73 ALDH1A1 (0.50) ALDH1A1KDM4ECYP1A2MAPTHPGD
SCHEMBL17452191 0.72 CYP1A2 (0.34) ALDH1A1KDM4ECYP1A2MAPTHPGD
SCHEMBL8304526 0.72 POLB (0.52) ALDH1A1KDM4EMAPTHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365582-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF KANAPH THERAPEUTICS INC. (KR) 2023-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365582-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF PTGER1, PTGIR, PTGDR2 ALDH1A1 1126/4885KDM4E 4594/4885CYP1A2 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.